These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
4. Three-Year Safety and Efficacy of the 0.19-mg Fluocinolone Acetonide Intravitreal Implant for Diabetic Macular Edema: The PALADIN Study. Singer MA; Sheth V; Mansour SE; Coughlin B; Gonzalez VH Ophthalmology; 2022 Jun; 129(6):605-613. PubMed ID: 35063472 [TBL] [Abstract][Full Text] [Related]
5. Three-year results from the Retro-IDEAL study: Real-world data from diabetic macular edema (DME) patients treated with ILUVIEN Augustin AJ; Bopp S; Fechner M; Holz F; Sandner D; Winkgen AM; Khoramnia R; Neuhann T; Warscher M; Spitzer M; Sekundo W; Seitz B; Duncker T; Ksinsik C; Höh H; Gentsch D Eur J Ophthalmol; 2020 Mar; 30(2):382-391. PubMed ID: 30884972 [TBL] [Abstract][Full Text] [Related]
6. Fluocinolone acetonide for the treatment of diabetic macular edema. Veritti D; Sarao V; Diplotti L; Samassa F; Lanzetta P Expert Opin Pharmacother; 2017 Oct; 18(14):1507-1516. PubMed ID: 28764565 [TBL] [Abstract][Full Text] [Related]
7. Evaluation of the clinical effectiveness of fluocinolone acetonide 190 µg intravitreal implant in diabetic macular edema: a comparison between study and fellow eyes. Currie CJ; Holden SE; Berni E; Owens DR Curr Med Res Opin; 2017 Oct; 33(sup2):19-31. PubMed ID: 28881143 [TBL] [Abstract][Full Text] [Related]
8. Effectiveness and tolerability of the fluocinolone acetonide implant in patients with diabetic macular edema in UAE: 12-Month results. Elbarky AM Eur J Ophthalmol; 2021 Nov; 31(6):3196-3202. PubMed ID: 33426902 [TBL] [Abstract][Full Text] [Related]
9. Report of 12-months efficacy and safety of intravitreal fluocinolone acetonide implant for the treatment of chronic diabetic macular oedema: a real-world result in the United Kingdom. Alfaqawi F; Lip PL; Elsherbiny S; Chavan R; Mitra A; Mushtaq B Eye (Lond); 2017 Apr; 31(4):650-656. PubMed ID: 28106887 [TBL] [Abstract][Full Text] [Related]
10. Fluocinolone Acetonide Intravitreal Implant 190 μg (ILUVIEN®) in Vitrectomized versus Nonvitrectomized Eyes for the Treatment of Chronic Diabetic Macular Edema. Pessoa B; Coelho J; Correia N; Ferreira N; Beirão M; Meireles A Ophthalmic Res; 2018; 59(2):68-75. PubMed ID: 29248913 [TBL] [Abstract][Full Text] [Related]
11. The Outcomes of Switching from Short- to Long-Term Intravitreal Corticosteroid Implant Therapy in Patients with Diabetic Macular Edema. Vaz-Pereira S; Castro-de-Sousa JP; Martins D; Prates Canelas J; Reis P; Sampaio A; Urbano H; Kaku P; Nascimento J; Marques-Neves C Ophthalmic Res; 2020; 63(2):114-121. PubMed ID: 31801148 [TBL] [Abstract][Full Text] [Related]
12. The 0.19-mg Fluocinolone Acetonide Intravitreal Implant for Diabetic Macular Edema: Intraocular Pressure-Related Effects over 36 Months. Roth DB; Eichenbaum D; Malik D; Radcliffe NM; Cutino A; Small KW; Ophthalmol Retina; 2024 Jan; 8(1):49-54. PubMed ID: 37586482 [TBL] [Abstract][Full Text] [Related]
13. The long-term efficacy and safety of fluocinolone acetonide intravitreal implant 190 μg (ILUVIEN Panos GD; Arruti N; Patra S Eur J Ophthalmol; 2021 Mar; 31(2):620-629. PubMed ID: 31906704 [TBL] [Abstract][Full Text] [Related]
14. Discontinuous to continuous therapy for persistent diabetic macular edema leads to reduction in treatment frequency. Adams OE; Schechet SA; Hariprasad SM Eur J Ophthalmol; 2021 Mar; 31(2):612-619. PubMed ID: 31964171 [TBL] [Abstract][Full Text] [Related]
15. Vitreous cytokine levels following the administration of a single 0.19 mg fluocinolone acetonide (ILUVIEN®) implant in patients with refractory diabetic macular edema (DME)-results from the ILUVIT study. Deuchler SK; Schubert R; Singh P; Chedid A; Kenikstul N; Scott J; Kohnen T; Ackermann H; Koch F Graefes Arch Clin Exp Ophthalmol; 2022 Aug; 260(8):2537-2547. PubMed ID: 35239010 [TBL] [Abstract][Full Text] [Related]
16. Clinical efficacy and safety of intravitreal fluocinolone acetonide implant for the treatment of chronic diabetic macular oedema: five-year real-world results. Dobler E; Mohammed BR; Chavan R; Lip PL; Mitra A; Mushtaq B Eye (Lond); 2023 Aug; 37(11):2310-2315. PubMed ID: 36513858 [TBL] [Abstract][Full Text] [Related]
17. Comparison of data characterizing the clinical effectiveness of the fluocinolone intravitreal implant (ILUVIEN) in patients with diabetic macular edema from the real world, non-interventional ICE-UK study and the FAME randomized controlled trials. Holden SE; Kapik B; Beiderbeck AB; Currie CJ Curr Med Res Opin; 2019 Jul; 35(7):1165-1176. PubMed ID: 30569759 [No Abstract] [Full Text] [Related]
18. The 0.19-mg Fluocinolone Acetonide Intravitreal Implant Reduces Treatment Burden in Diabetic Macular Edema. Merrill PT; Holekamp N; Roth D; Kasper J; Grigorian R; Am J Ophthalmol; 2023 Apr; 248():16-23. PubMed ID: 36223849 [TBL] [Abstract][Full Text] [Related]
19. Treatment of chronic diabetic macular oedema with intravitreal fluocinolone acetonide implant; real-life analysis of outcomes during overall treatment period. Cox L; Li Y; Fotuhi M; Vermeirsch S; Yeung I; Hamilton RD; Rajendram R; Lukic M Eur J Ophthalmol; 2022 Nov; 32(6):3629-3636. PubMed ID: 35484812 [TBL] [Abstract][Full Text] [Related]
20. Outcomes in diabetic macular edema switched directly or after a dexamethasone implant to a fluocinolone acetonide intravitreal implant following anti-VEGF treatment. Rehak M; Busch C; Unterlauft JD; Jochmann C; Wiedemann P Acta Diabetol; 2020 Apr; 57(4):469-478. PubMed ID: 31749051 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]